This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Glenny AT, Pope CG, Waddington H, Wallace U (1926) Immunological Notes. XVII–XXIV. J Pathol Bacteriol 29: 31–40
Aprile MA, Wardlaw, AC (1966) Aluminium compounds as adjuvants for vaccines and toxoids in man: A review. Can J Publ Hlth 57: 343–354
Gupta RK (1998) Aluminum compounds as vaccine adjuvants. Adv Drug Delivery Rev 32: 155–172
Lima KM, dos Santos SA, Rodrigues Jr JM, Silva CL (2004) Vaccine adjuvant: it makes the difference. Vaccine 22: 2374–2379
Ahlers JD, Dunlop N, Alling DW, Nara PL, Berzofsky JA (1997) Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs. Granulocyte-macrophage colony-stimulating factor and TNF-α synergize with IL-12 to enhance induction of cytotoxic t lymphocytes. J Immunol 158: 3947–3958
Elson CO, Ealding W (1984) Cholera toxin feeding did not induce oral tolerance in mice and abrogated oral tolerance to an unrelated protein antigen. J Immunol 133: 2892–2897
Snider DP (1995) The mucosal adjuvant activities of ADP-ribosylating bacterial enterotoxins. Crit Rev Immunol 15: 317–348
Glenn GM, Rao M, Matyas GR, Alving CR (1998) Skin immunization made possible by cholera toxin. Nature 391: 851
Glenn GM, Scharton-Kersten T, Vassell R, Matyas GR, Alving CR (1999) Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants. Infect Immun 67: 1100–1106
Kawamura YI, Kawashima R, Shirai Y, Kato R, Hambata T, Yamamoto M, Furukawa K, Fujihashi K, McGhee JR, Hayashi H et al (2003) Cholera toxin activates dendritic cells through dependence on GM1-ganglioside which is mediated by NF-κB translocation. Eur J Immunol 33: 3205–3212
Gupta RK, Relyveld EH, Lindblad EB, Bizzini B, Ben-Efraim S, Gupta CK (1993) Adjuvants — a balance between toxicity and adjuvanticity. Vaccine 11: 293–306
Edelman R (1980) Vaccine adjuvants. Rev Infect Dis 2: 370–383
Chang JCC, Diveley JP, Savary JR, Jensen FC (1998) Adjuvant activity of incomplete Freund’s adjuvant. Adv Drug Deliv Rev 32: 173–186
Davenport FM (1968) Seventeen years’ experience with mineral oil adjuvant influenza virus vaccines. Ann Allergy 26: 288–292
Stuart-Harris CH (1969) Adjuvant influenza vaccines. Bull WHO 41: 617–621
Alving CR (2002) Design and selection of vaccine adjuvants: animal models and human trials. Vaccine 20: S56–S64
Podda A (2001) The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 19: 2673–2680
Frey S, Poland G, Percell S, Podda A (2003) Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults. Vaccine 21: 4234–4237
Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J, Mandomando I, Spiessens B, Guinovart C, Espasa M et al (2004) Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 364: 1411–1429
Pearson CM (1956) Development of arthritis, periarthritis and periostitis in rats given adjuvants. Proc Soc Exp Biol Med 91: 95–101
Taurog JD, Argentieri DC, McReynolds RA (1988) Adjuvant arthritis. Meth Enzymol 162: 339–355
Durai M, Kim HR, Moudgil KD (2004) The regulatory C-terminal determinants within mycobacterial heat shock protein 65 are cryptic and cross-reactive with the dominant self homologs: Implications for the pathogenesis of autoimmune arthritis. J Immunol 173: 181–188
Kleinau S, Erlandsson H, Klareskog L (1994) Percutaneous exposure of adjuvant oil causes arthritis in DA rats. Clin Exp Immunol 96: 281–284
Salk JE, Contakos M, Laurent AM, Sorensen M, Rapalski AJ, Simmons IH, Sandberg H (1953) Use of adjuvants in studies on influenza immunization. 3. Degree of persistence of antibody in human subjects two years after vaccination. J Am Med Assn 151: 1169–1175
Beebe GW, Simon AH, Vivona S (1964) Follow-up study on army personnel who received adjuvant influenza virus vaccine 1951–1953. Am J Med Sci 247: 385–407
Beebe GW, Simon AH, Vivona S (1972) Long-term mortality follow-up of army recruits who received adjuvant influenza virus vaccine in 1951–1953. Am J Epidemiol 95: 337–346
Page WF, Norman JE, Benenson AS (1993) Long-term followup of army recruits immunized with Freund’s incomplete adjuvanted vaccine. Vaccine Res 2: 141–149
Baylor NW, Egan W, Richman P (2002) Aluminum salts in vaccines — US perspective. Vaccine 20: S18–S23
Wittayanukulluk A, Jiang D, Regnier FE, Hem SL (2004) Effect of microenvironment pH of aluminum hydroxide adjuvant on the chemical stability of adsorbed antigen. Vaccine 22: 1172–1176
Gupta RK, Rost BE, Relyveld E, Siber GR (1995) Adjuvant properties of aluminum and calcium compounds. In: Powell MF, Newman MJ (eds): Vaccine design, the subunit and adjuvant approach. New York: Plenum Press, 229–248
Jefferson T, Rudin M, Di Pietrantonj C (2004) Adverse events after immunisation with aluminium-containing DTP vaccines: systematic review of the evidence. Lancet Infect Dis 4: 84–90
Shirodkar S, Hutchinson RL, Perry DL, White JL, Hem SL (1990) Aluminum compounds used as adjuvants in vaccines. Pharmaceut Res 7: 1282–1288
Wassef NM, Alving CR, Richards RL (1994) Liposomes as carriers for vaccines. Immunomethods 4: 217–222
Hem SL, White JL (1995) Structure and properties of aluminum-containing adjuvants. Pharm Biotech 6: 249–276
Seeber SJ, White JL, Hem SL (1991) Solubilization of aluminum-containing adjuvants by constituents of interstitial fluid. J Parenteral Sci Technol 45: 156–159
Heimlich JM, Regnier FE, White JL, Hem SL (1999) The in vitro displacement of adsorbed model antigens from aluminium-containing adjuvants by interstitial proteins. Pharm Biotech 17: 2873–2881
Iyer S, HogenEsch H, Hem SL (2003) Relationship between the degree of antigen adsorption to aluminum hydroxide adjuvant in interstitial fluid and antibody production. Vaccine 21: 1219–1223
Morefield GL, HogenEsch H, Robinson JP, Hem SL (2004) Distribution of adsorbed antigen in mono-valent and combination vaccines. Vaccine 22: 1973–1984
Burrell LS, White JL, Hem SL (2000) Stability of aluminium-containing adjuvants during aging at room temperature. Vaccine 18: 2188–2192
Seeber SJ, White JL, Hem SL (1991) Predicting the adsorption of proteins by aluminium-containing adjuvants. Vaccine 9: 201–203
Callahan PM, Shorter AL, Hem SL (1991) The importance of surface charge in the optimization of antigen-adjuvant interactions. J Pharmaceut Res 8: 851–858
Feldkamp JR, Shah DN, Meyer SL, White JL, Hem SL (1981) Effect of adsorbed carbonate on surface charge characteristics and physical properties of aluminum hydroxide gel. J Pharmaceut Sci 70: 638–640
Rinella Jr JV, White JL, Hem SL (1996) Treatment of aluminium hydroxide adjuvant to optimize the adsorption of basic proteins. Vaccine 14: 298–300
Iyer S, Robinett RSR, HogenEsch H, Hem SL (2004) Mechanism of adsorption of hepatitis B surface antigen by aluminum hydroxide adjuvant. Vaccine 22: 1475–1479
Alving CR, Shichijo S, Mattsby-Baltzer I, Richards RL, Wassef NM (1993) Preparation and use of liposomes in immunological studies. In: Gregoriadis G (ed): Liposome technology, 2nd edition, Vol III, Interactions of liposomes with the biological milieu. Boca Raton: CRC Press, 317–343
Hem SL (2002) Elimination of aluminum adjuvants. Vaccine 20(Suppl 3): S40–S43
Gupta RK, Siber GR (1995) Adjuvants for human vaccines — current status, problems and future prospects. Vaccine 13: 1263–1276
Frost L, Johansen P, Pedersen S, Veien N, Østergaard PA, Nielsen MH (1985) Persistent subcutaneous nodules in children hyposensitized with aluminium-containing allergen extracts. Allergy 40: 368–372
Pittman PR (2002) Aluminum-containing vaccine associated adverse events: role of route of administration and gender. Vaccine 20: S48–S50
Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, Spyr C, Steffen R (2004) Use of the inactivated intranasal influenza vaccine and the risk of Bell’s palsy in Switzerland. N Engl J Med 350: 896–903
Couch RB (2004) Nasal vaccination, Escherichia coli enterotoxin, and Bell’s palsy. N Engl J Med 350: 860–861
Eidels L, Proia RL, Hart DA (1983) Membrane receptors for bacterial toxins. Microbiol Rev 47: 596–620
Takada H, Kotani S (1989) Structural requirements of lipid A for endotoxicity and other biological activities. CRC Crit Rev Microbiol 16: 477–523
Alving CR (1993) Lipopolysaccharide, lipid A, and liposomes containing lipid A as immunologic adjuvants. Immunobiol 187: 430–446
Richards RL, Swartz Jr GM, Schultz C, Hayre MD, Ward GS, Ballou WR, Chulay JD, Hockmeyer WT, Berman SL, Alving CR (1989) Immunogenicity of liposomal malaria sporozoite antigen in monkeys: adjuvant effects of aluminum hydroxide and nonpyrogenic liposomal lipid A. Vaccine 7: 506–512
Fries LF, Gordon DM, Richards RL, Egan JE, Hollingdale MR, Gross M, Silverman C, Alving CR (1992) Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. Proc Natl Acad Sci USA 89: 358–362
Calarota SA, Weiner DB (2004) Enhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvants. Immunol Rev 199: 84–99
Toka FN, Pack CD, Rouse BT (2004) Molecular adjuvants for mucosal immunity. Immunol Rev 199: 100–112
Pizza M, Giuliani MM, Fontana MR, Monaci E, Douce G, Dougan G, Mills KHG, Rappuoli R, Del Giudice G (2001) Mucosal vaccines: non-toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 19: 2534–2541
Glenn GM, Taylor DN, Li X, Frankel S, Montemarano A, Alving CR (2000) Transcutaneous immunization: A human vaccine delivery strategy using a patch. Nature Med 6: 1403–1406
Belyakov IM, Hammond SA, Ahlers JD, Glenn GM, Berzofsky JA (2004) Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J Clin Invest 113: 998–1007
Güereña-Burgueño F, Hall ER, Taylor DN, Cassels FJ, Scott DA, Wolf MK, Roberts ZJ, Nesterova GV, Alving CR, Glenn GM (2002) Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously. Infect Immun 70: 1874–1880
Nossal GJV (1999) Vaccines. In: Paul WE (ed): Fundamental immunology. Philadelphia: Lippincott-Raven, 1387–1425
Pulendran B (2004) Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunol Rev 199: 227–250
Goldenthal KL, Cavagnaro JA, Alving CR, Vogel FR (1993) Safety evaluation of vaccine adjuvants: National Cooperative Vaccine Development Meeting Working Group. AIDS Res Hum Retrovir 9(Suppl 1): S47–S51
Sesardic D, Dobbelaer R (2004) European union regulatory developments for new vaccine adjuvants and delivery systems. Vaccine 22: 2452–2456
Kenney RT, Edelman R (2004) Adjuvants for the future. In: Levine MM, Kaper JB, Rappuoli R, Liu MA, Good MF (eds): New generation vaccines, 3rd edition. New York: Marcel Dekker, 213–223
Glück R, Mischler R, Finkel B, Que JU, Scarpa B, Cryz Jr SJ (1994) Immunogenicity of new virosome influenza vaccine in elderly people. Lancet 344: 160–163
Sondak VK, Sosman JA (2003) Results of clinical trials with an allogenic melanoma tumor lysate vaccine: Melacine. Semin Cancer Biol 13: 409–415
Heppner DG, Gordon DM, Gross M, Wellde B, Leitner W, Krzych U, Schneider I, Wirtz RA, Richards RL, Trofa A et al (1996) Safety, immunogenicity and efficacy of plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomes. J Inf Dis 174: 361–366
McElrath MJ (1995) Selection of potent immunological adjuvants for vaccine construction. Sem Cancer Biol 6: 375–385
Harris DT, Matyas GR, Gomella LG, Taylor E, Winship MD, Spitler LE, Mastrangelo MJ (1999) Immunologic approaches to the treatment of prostate cancer. Sem Oncol 26: 439–447
Reid CDL, Stackpole A, Meager A, Tikerpae J (1992) Interactions of tumor necrosis factor with granulocyte-macrophage colony-stimulating factor and other cytokines in the regulation of dendritic cell growth in vitro from early bipotent CD34+ progenitors in human bone marrow. J Immunol 149: 2681–2688
Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90: 3539–3543
Samanci A, Yi Q, Fagerberg J, Strigård K, Smith G, Rudén U, Wahren B, Mellsted H (1998) Pharmacological administration of granulocyte/marcophage-colony stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen. Cancer Immunol Immunother 47: 131–142
Disis ML, Bernhard H, Shiota FM, Hand SL, Gralow JR, Huseby ES, Gillis S, Cheever MA (1996) Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood 88: 202–210
Ragnhammar P, Fagerberg J, Frödin JE, Wersäll P, Hansson LO, Mellstedt H (1995) Granulocyte/macrophage-colony-stimulating factor augments the induction of antibodies, especially anti-idiotypic antibodies, to therapeutic monoclonal antibodies. Cancer Immunol Immunother 40: 367–375
Meidenbauer N, Gooding W, Spitler L, Harris D, Whiteside TL (2002) Recovery of zeta-chain expression and changes in spontaneous IL-10 production after PSA-based vaccines in patients with prostate cancer. Br J Cancer 86: 168–178
Berd D, Mastrangelo MJ, Engstrom PF, Paul A, Maguire H (1982) Augmentation of the human immune response by cyclophosphamide. Cancer Res 42: 4862–4866
Berd D, Maguire Jr HC, Mastrangelo MJ (1986) Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell baccine preceded by cyclophosphamie. Cancer Res 46: 2572–2577
Hanna MG Jr, Peters LC, Hoover HC Jr (1989) Fundamentals of active specific immunotherapy of cancer using BCG-tumor cell vaccines. Prog Clin Biol Res 310: 51–65
Leong SP, Enders-Zohr P, Zhou YM, Stuntebeck S, Habib FA, Allen RE Jr, Sagebiel RW, Glassberf AB, Lowenberg DW, Hayes FA (1999) Recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) and autologous melanoma vaccine mediate tumor regression in patients with metastatic melanoma. J Immunother 22: 166–174
Muderhwa JM, Matyas GR, Spitler LE, Alving CR (1999) Oil-in-water liposomal emulsions: characterization and potential use in vaccine delivery. J Pharm Sci 88: 1332–1339
Matyas GR, Muderhwa JM, Alving CR (2003) Oil-in-water liposomal emulsions for vaccine delivery. Meth Enzymol 373: 34–50
Lotze MT, Rosenberg SA (1991) Interleukin-2: clinical applications. In: DeVita J, Hellman S, Rosenberg SA (eds): Biologic therapy of cancer. JD Lippencott, Philadelphia, 159–177
Hladik F, Tratkiewicz JA, Tilg H, Vogel W, Schwulera V, Krönke M, Aulitzky WE, Huber C (1999) Biologic activity of low dosage IL-2 treatment in vivo. Molecular assessment of cytokine network interaction. J Immunol 153: 1449–1454
Meidenbauer N, Harris DT, Spitler LE, Whiteside TL (2000) Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer. The Prostate 43: 88–100
Neidhart J, Allen KO, Barlow DL, Carpenter M, Shaw DR, Triozzi PL, Conry RM (2004) Immunization of colorectal cancer patients with recombinant baculovirus-drived KSA (Ep-CAM) formulated with monophosphoryl lipid A in liposomal emulsion, with and without granulocyte-macrophage colony factor. Vaccine 22: 773–780
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Copyright information
© 2005 Birkhäuser Verlag
About this chapter
Cite this chapter
Alving, C.R., Matyas, G.R. (2005). Design and selection of vaccine adjuvants: principles and practice. In: Kaufmann, S.H., Lambert, PH. (eds) The Grand Challenge for the Future. Birkhäuser Advances in Infectious Diseases BAID. Birkhäuser Basel. https://doi.org/10.1007/3-7643-7381-4_6
Download citation
DOI: https://doi.org/10.1007/3-7643-7381-4_6
Publisher Name: Birkhäuser Basel
Print ISBN: 978-3-7643-7175-3
Online ISBN: 978-3-7643-7381-8
eBook Packages: MedicineMedicine (R0)